Chemotherapy for Esophageal Adenocarcinoma

  • Ka-On Lam
  • Dora L. W. Kwong
Part of the Methods in Molecular Biology book series (MIMB, volume 1756)


Esophageal and esophagogastric junction adenocarcinoma is a distinct entity from esophageal squamous cell carcinoma with respect to etiology and biology despite sharing the same anatomical location. While most international treatment guidelines recommend a similar management strategy for both esophageal squamous and adenocarcinoma histologies, the evidence for treating adenocarcinoma are indeed more often extrapolated from that of gastric carcinoma. In this chapter, the best evidences for the management of this distinct disease with chemotherapy in both curative and palliative clinical settings are presented.

Key words

Esophageal adenocarcinoma Esophagogastric junction adenocarcinoma Chemotherapy Preoperative Perioperative Palliative 


  1. 1.
    Rustgi AK, El-Serag HB (2014) Esophageal carcinoma. N Engl J Med 371:2499–2509CrossRefPubMedGoogle Scholar
  2. 2.
    Hur C, Miller M, Kong CY et al (2013) Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119:1149–1159CrossRefPubMedGoogle Scholar
  3. 3.
    Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287:1972–1981CrossRefPubMedGoogle Scholar
  4. 4.
    Cook MB, Kamangar F, Whiteman DC et al (2010) Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst 102:1344–1353CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tramacere I, Pelucchi C, Bagnardi V et al (2012) A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol 23:287–297CrossRefPubMedGoogle Scholar
  6. 6.
    Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G (2007) Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 5:1413–1417CrossRefPubMedGoogle Scholar
  7. 7.
    NCCN Guidelines on esophageal and esophagogastric Junction Cancers. Version 1.2017Google Scholar
  8. 8.
    Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D (2016) Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v50–v57CrossRefPubMedGoogle Scholar
  9. 9.
    Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984CrossRefPubMedGoogle Scholar
  10. 10.
    Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, Radiation Therapy Oncology Group; USA Intergroup (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25:3719–37125CrossRefPubMedGoogle Scholar
  11. 11.
    Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727–1733CrossRefGoogle Scholar
  12. 12.
    Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27:5062–5067CrossRefGoogle Scholar
  13. 13.
    Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185:538–543CrossRefPubMedGoogle Scholar
  14. 14.
    Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials Group (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20CrossRefGoogle Scholar
  17. 17.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721CrossRefGoogle Scholar
  18. 18.
    Al-Batran SE, Hofheinz RD, Pauligk C et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17:1697–1708CrossRefGoogle Scholar
  19. 19.
    MacDonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730CrossRefGoogle Scholar
  20. 20.
    Smalley SR, Benedetti JK, Haller DG (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2008) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820CrossRefGoogle Scholar
  22. 22.
    Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefPubMedGoogle Scholar
  23. 23.
    Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321CrossRefPubMedGoogle Scholar
  24. 24.
    Noh SH, Park SR, Yang HK et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15:1389–1396CrossRefPubMedGoogle Scholar
  25. 25.
    Lasithiotakis K, Antoniou SA, Antoniou GA et al (2014) Gastrectomy for stage IV gastric cancer. A systematic review and meta-analysis. Anticancer Res 34:2079–2085PubMedGoogle Scholar
  26. 26.
    Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909CrossRefPubMedGoogle Scholar
  27. 27.
    Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 17:CD004064Google Scholar
  28. 28.
    Blum JL (2000) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56–64CrossRefGoogle Scholar
  29. 29.
    Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRefPubMedGoogle Scholar
  30. 30.
    Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673CrossRefPubMedGoogle Scholar
  31. 31.
    Chap LI, Laux I, VanVugt A et al (2008) A phase I study of S-1 GI toxicity with and without oxonic acid (Oxo). J Clin Oncol 26:623s. (abstr 13539)CrossRefGoogle Scholar
  32. 32.
    Saif MW, Rosen LS, Zhang J et al (2008) A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics (PK) of 5-fluorouracil (5-FU). J Clin Oncol 26:115s. (abstr 2514)CrossRefGoogle Scholar
  33. 33.
    Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069CrossRefPubMedGoogle Scholar
  34. 34.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221CrossRefPubMedGoogle Scholar
  35. 35.
    Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547–1553CrossRefPubMedGoogle Scholar
  36. 36.
    He MM, Wu WJ, Wang F et al (2013) S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis. PLoS One 8:e82798CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kobayashi M, Tsuburaya A, Nishikawa K et al (2015) A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II). J Clin Oncol 33(Suppl 3; abstr 105)Google Scholar
  38. 38.
    Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442CrossRefGoogle Scholar
  39. 39.
    Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 26:141–148CrossRefGoogle Scholar
  40. 40.
    Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997CrossRefPubMedGoogle Scholar
  41. 41.
    Al-Batran SE, Hartmann JT, Hofheinz R et al (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19:1882–1887CrossRefPubMedGoogle Scholar
  42. 42.
    Overman MJ, Kazmi SM, Jhamb J et al (2010) Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116:1446–1453CrossRefPubMedGoogle Scholar
  43. 43.
    Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J, Australasian Gastro-Intestinal Trials Group (2010) Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102:475–481CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Koizumi W, Kim YH, Fujii M et al (2014) Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 140:319–328CrossRefPubMedGoogle Scholar
  45. 45.
    Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450–1457CrossRefPubMedGoogle Scholar
  46. 46.
    Guimbaud R, Louvet C, Ries P et al (2014) Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32:3520–3526CrossRefPubMedGoogle Scholar
  47. 47.
    Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306–2314CrossRefPubMedGoogle Scholar
  48. 48.
    Ford HE, Marshall A, Bridgewater JA (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78–86CrossRefPubMedGoogle Scholar
  49. 49.
    Janowitz T, Thuss-Patience P, Marshall A et al (2016) Chemotherapy vs. supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer 114:381–387CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Kang JH, Lee SI, Lim DH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513–1518CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of Clinical Oncology, LKS Faculty of MedicineThe University of Hong Kong, Queen Mary HospitalPokfulamHong Kong

Personalised recommendations